Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 10/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 17/20 | 0.55 |
| ▸ | HTR3E | A5X5Y0 | 8/20 | 0.55 |
| ▸ | HTR3B | O95264 | 8/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 8/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 8/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205007 | 0.85 | CHRNA7 (0.67) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL4205011 | 0.85 | CHRNA7 (0.67) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL7059422 | 0.84 | CHRNA7 (0.65) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL4200282 | 0.84 | CHRNA7 (0.75) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL4198184 | 0.84 | CHRNA7 (0.75) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL7688113 | 0.82 | CHRNA7 (0.56) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL7225969 | 0.82 | HTR3A (0.59) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL7218271 | 0.80 | HTR3A (0.53) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL4195001 | 0.80 | CHRNA7 (0.54) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL4196158 | 0.80 | CHRNA7 (0.54) | HTR3ACHRNA7HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | HTR3A 1069/4885CHRNA7 28/4885HTR3E 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.